# Adolescents and young adults: a group with its own cancers, its own gap and its own needs

Source: https://onco.cc/technologies/rejuv-ayac-distinct-group/  
OnCo record `rejuv-ayac-distinct-group` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

People diagnosed between 15 and 39 get different cancers from children and from older adults, and for years their survival improved more slowly than either. Since 2000 that has changed: five-year survival gains for this group have paralleled those of childhood cancers. The obstacles that remain are trial enrolment, access and insurance, and support that fits the age.

## Summary

Adolescent and young adult oncology exists as a field because the people in it fell between two services. The cancers are their own: lymphomas, germ cell tumours, thyroid cancer, melanoma, sarcomas, brain tumours, leukaemias and, increasingly, early-onset breast and bowel cancers, in a mix that matches neither paediatric nor older-adult practice. The services are not their own: a nineteen-year-old with leukaemia may be treated on a paediatric protocol in a children's hospital or an adult protocol in an adult one, and the two differ.

The scale. In the United States, "There are nearly 70,000 new cancer diagnoses made annually in adolescents and young adults (AYAs)", aged 15 to 39. In the United Kingdom, Cancer Research UK records 2,409 new cases a year among people aged 15 to 24, against 1,987 a year in children aged 0 to 14. These are rare cancers in absolute terms, which is itself part of the problem: no district general hospital sees enough of them.

The survival gap, and its closing. The 2019 review of the field states that "Historically, AYA patients with cancer, aged 15 to 39 years, have not shown the same improved survival as older or younger cohorts", and then the encouraging half: "absolute and relative increases in 5-year survival for AYA cancers have paralleled those of childhood cancers since the year 2000". In the United Kingdom, Cancer Research UK reports that almost 9 in 10 (87 per cent) of people diagnosed at ages 15 to 24 survive five years or more (2012 to 2016), more than 8 in 10 (83 per cent) survive ten years or more (2007 to 2011), and more than 7 in 10 (74 per cent) survive twenty years or more (1997 to 2001). For comparison, 84 per cent of children aged 0 to 14 survive five years or more (2012 to 2016).

The three vulnerabilities. The same review groups what remains into "research efforts and trial enrollment directed toward AYA malignancies, access to care and insurance coverage, and AYA-specific psychosocial support", and warns that "the AYA population remains vulnerable to provider and societal complacency". Each of the three has its own record in this front: diagnostic delay, education and work, and the services built for this age group.

Why recovery is a different question at this age. A diagnosis at nineteen interrupts the things that set up the rest of a life: education, first jobs, leaving home, forming relationships, deciding about children. The physical late effects are the same organs as elsewhere in this front, but the cost of losing fertility, of two years out of education, or of being uninsurable is larger because there is more life ahead of it. That is why survivorship for this group is as much about education, employment and relationships as about echocardiograms.

What comes back, and when: most of it, and sooner than people expect, but not without help. The specific records alongside this one set out what is known about each piece.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; paediatric; late-effects; evidence:moderate
- Principle: Cancers arising between 15 and 39 are biologically distinct from both paediatric embryonal tumours and the carcinomas of later life, so protocols derived from either population may be the wrong ones. Service design compounds the biology: enrolment on clinical trials is lowest in this age band, and care is split between paediatric and adult systems with different protocols, different trial portfolios and different supportive care, which is the mechanism most often proposed for the historical survival gap.
- Strengths: Five-year survival gains since 2000 have paralleled those in childhood cancer; The field is now defined, with its own journals, services and guidelines; The specific obstacles are named rather than vague
- Limitations: Trial enrolment remains lowest in this age band; Care is split between paediatric and adult systems with different protocols; Access and insurance are a major determinant of outcome in some health systems

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Adolescent_and_young_adult_oncology
- Adolescent and young adult oncology: past, present and future (CA Cancer J Clin 2019): https://doi.org/10.3322/caac.21585
- Cancer Research UK: young people's cancers statistics: https://www.cancerresearchuk.org/health-professional/cancer-statistics/teenagers-and-young-adults-cancers
- Cancer Research UK: children's cancer statistics: https://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers

## Connected records

- institutions: [Teenage Cancer Trust](https://onco.cc/institutions/teenage-cancer-trust/)
- journals: [Journal of adolescent and young adult oncology](https://onco.cc/journals/journal-of-adolescent-and-young-adult-oncology/)
- ideas: [A survivorship passport app for adolescent and young adult survivors](https://onco.cc/ideas/idea-acc-aya-survivorship-passport/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Osteosarcoma](https://onco.cc/cancers/osteosarcoma/), [Testicular germ cell tumours](https://onco.cc/cancers/testicular/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Education, work and the years that were interrupted](https://onco.cc/technologies/rejuv-ayac-education-and-work/), [How long it takes to diagnose cancer in a young person, and what the evidence actually says](https://onco.cc/technologies/rejuv-ayac-diagnostic-delay/), [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [Services built for teenagers and young adults, and what the national evaluation found](https://onco.cc/technologies/rejuv-ayac-services/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/)
- terms: [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Quality of life](https://onco.cc/terms/quality-of-life/)
- bottlenecks: [Fragmented care and guideline gaps](https://onco.cc/bottlenecks/b-care-fragmentation/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-ayac-distinct-group.json